- Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatmentPatrick R Harrington
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, MD 20993, USA
Hepatology 55:1048-57. 2012..Analyses of Phase 2 boceprevir and telaprevir trials indicated subjects with detectable/BLOQ HCV RNA at RGT timepoints benefited from extended treatment duration...
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvirEric F Donaldson
Division of Antiviral Products, U S Food and Drug Administration, Silver Spring, MD
Hepatology 61:56-65. 2015..Analyses of these variants modeled in NS5B crystal structures indicated that all four substitutions could feasibly affect SOF anti-HCV activity...
- Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathwaysTakashi E Komatsu
Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA Electronic address
Antiviral Res 101:12-25. 2014....